Navigation Links
Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
Date:2/2/2011

AUSTIN, Texas, Feb. 2, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.

"The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Austin, Texas. Additional information about Vermillion can be found on the Web at www.vermillion.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Announces Issuance of European Patent
2. Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19
3. Medicare Establishes Reimbursement Coverage for Vermillions OVA1(TM) Test
4. Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors
5. Vermillion Announces Return of Eric Fung, M.D., Ph.D.
6. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
7. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
8. Vermillion Announces Receipt of NASDAQ Panel Decision
9. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
10. International Isotopes Inc. Announces a Shareholder Conference Call for February 7, 2011
11. Advanced Health Media Company Announces Renee DeFranco as Senior Vice President - Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/30/2019)... , ... January 29, 2019 , ... ... (AskBio), today announced the dosing of the first patient in a phase 1/2 ... a serious disease associated with high morbidity and often leads to premature death. ...
(Date:1/30/2019)... WHITEHOUSE, N.J. (PRWEB) , ... January 30, 2019 ... ... brings together experts from pharma, academia and governmental agencies to discuss best practices ... Washington, DC from February 4-6. , At this year’s conference, Visikol will ...
(Date:1/28/2019)... SAN DIEGO (PRWEB) , ... January 28, 2019 ... ... proteins against libraries of low molecular weight compounds. In this early stage, false ... binding. At the same time, it is vital that screening techniques are highly ...
(Date:1/24/2019)... (PRWEB) , ... January 22, 2019 , ... ... since each trial has its own set of assumptions, and RFP creation and ... so evaluating bids is like comparing apples to oranges. These challenges can ultimately ...
Breaking Biology Technology:
(Date:2/12/2019)... SASKATOON, Canada (PRWEB) , ... February 12, 2019 ... ... immediately it will begin operating under its new name, KEYLEAF. The company ... more of its own plant-based extracts and ingredients as finished products under the ...
(Date:2/2/2019)... ... January 31, 2019 , ... ... , geared toward clinical operations executives and focusing on all facets of clinical ... effective project management, portfolio management, resource management, patient engagement, and more. , ...
(Date:1/25/2019)... ... January 24, 2019 , ... ... PhD, Assistant Professor of Microbiology at the Jackson Laboratory (JAX), to its Scientific ... world, Dr. Oh will bring to uBiome expertise in skin microbial interactions and ...
Breaking Biology News(10 mins):